Rhythm Biosciences Limited Overview
Rhythm Biosciences is a Melbourne-based, commercial-stage precision diagnostics micro-cap that has spent eight years converting CSIRO-originated science into two marketable cancer-detection platforms. Its flagship, ColoSTAT, is a blood test measuring five protein biomarkers to indicate the likelihood of colorectal cancer, now offered in Australia as an in-house IVD from the company's NATA/ISO 15189-accredited Parkville laboratory, with ordering embedded in GP software and samples collected through 4Cyte Pathology's network. Its second platform, geneType, acquired out of administration in December 2024 for A$0.52M cash, provides polygenic and clinical risk assessment across nine tests and gives Rhythm a US footprint. FY26 marked the transition from development to first sales (A$85,339), but the business remains deeply loss-making (FY26 loss A$5.93M), carries a going-concern material uncertainty, and depends on continued equity funding. The investment case rests on converting clinical interest, an NHS England evaluation and reimbursement work into scalable test volumes.
Company's own description (FY26 Annual Report / Appendix 4E)
In its FY26 Directors' Report the company describes itself as an innovative Australian, publicly listed medical diagnostics company focused on delivering simple, affordable blood tests for the accurate detection of cancers, providing physicians with accurate and reliable diagnostic tools. The Directors characterise FY26 as the year in which Rhythm moved from development to commercialisation, with both diagnostic platforms — ColoSTAT and geneType — recording clinical sales. In its Q4 FY26 activities report, the company described itself as a commercial-stage precision diagnostics company. Segment Note 19 states the group operates in one business — the development and commercialisation of cancer diagnostic tests — in Victoria, Australia and the United States.
Independent characterisation
Rhythm is best understood as a laboratory-service diagnostics company in its first year of revenue, rather than a kit manufacturer. Its current Australian model has four elements:
-
Clinician demand generation — GPs and specialists order ColoSTAT, increasingly via an electronic request form integrated into MedicalDirector (live 1 August 2026), supported by a direct ColoSTAT Access Program and an Ausdoc-delivered awareness campaign targeting approximately 20,000 GPs (July 2026).
-
Sample logistics via partners — patients have blood drawn at 4Cyte Pathology collection centres (agreement signed February 2026; network covering more than 1,000 centres across NSW, Victoria and Queensland, with 100+ sites activated for ColoSTAT by August 2026). 4Cyte operates on a per-test basis with no upfront payments or minimum commitments.
-
Centralised testing — all ColoSTAT samples are analysed at Rhythm's own ISO 15189:2022/NATA-accredited Parkville laboratory, under a TGA in-house IVD notification accepted in August 2026.
-
Direct patient billing — Rhythm invoices patients directly; ColoSTAT is not currently funded by Medicare (company announcement, 7 October 2026). The health-economic model published that day assumed A$250 per test.
The geneType platform runs a parallel B2B2C and channel-partner model: tests are ordered through healthcare providers and genetic counsellors, and distributed via partners (Catch Bio and Cancer IQ in the US; an unnamed Southeast Asian distributor launching in the Philippines; the Australian Genome Research Facility for domestic scale-up).
Internationally, the company is pursuing a technology-transfer / laboratory-partner model, in which third-party laboratories run ColoSTAT using Rhythm's reagent kits (manufactured under contract by US-based Quansys Biosciences). The completion of technology transfer to the NHS Southern Hub laboratory in September 2026 is the first proof that a third party can run the assay.
Revenue model mix
| Revenue type | Status (FY26) | Comment |
|---|---|---|
| Product (kit sales) | Not yet material | Kit sales to third-party labs are the intended international model; none disclosed as revenue in FY26 |
| Service (laboratory testing) | Primary | ColoSTAT and geneType tests performed in-house and billed per test |
| Subscription | — | Not applicable |
| Licensing / royalties | None received | Rhythm is a licensee (pays CSIRO a 2% royalty on ColoSTAT sales per IPO-era disclosure) |
| Government income (R&D tax incentive) | Dominant non-operating inflow | A$1.576M received in FY26; A$3.166M in FY25 |
The statutory P&L does not split sales revenue by platform. Total sales revenue was A$85,339 in FY26 versus A$25,126 in FY25 (the latter entirely from geneType following acquisition).
Value-chain position
Rhythm sits in the assay development, regulatory and testing-service layer. It outsources reagent kit manufacture (Quansys Biosciences, USA, multi-year agreement with two years of fixed pricing; previously Biotem, France, appointed December 2020), outsources phlebotomy and specimen logistics (4Cyte Pathology), and relies on GP software vendors (MedicalDirector) for ordering. It retains all IP and data, the accredited laboratory, the algorithm, and the clinical/regulatory dossier.
Customer types and end-markets
| Customer / payer | Product | Market |
|---|---|---|
| General practitioners (referrers) | ColoSTAT | Australia (eastern states first) |
| Specialists (gastroenterologists, colorectal surgeons) | ColoSTAT | Australia |
| Patients (self-pay) | ColoSTAT, geneType | Australia |
| Public health systems (prospective) | ColoSTAT | UK (NHS England evaluation), Australian public hospitals (health-economic case) |
| Genetic counsellors, clinicians | geneType | Australia, US |
| Digital health / prevention platforms | geneType | US (Catch Bio, Cancer IQ) |
| Distributors | geneType | Southeast Asia (Philippines initial) |
End-markets: colorectal cancer triage and screening (symptomatic and screening-hesitant populations), and polygenic risk assessment for cancers and chronic disease.
Strategy
Stated strategy (themes from FY26 Annual Report, quarterly reports and investor presentations)
Management's framing centres on four themes:
-
"From research to revenue." The January 2026 quarterly headline described ColoSTAT's business update in these terms, and the April 2026 quarterly declared Rhythm no longer a development-stage company but a commercial diagnostics business with two revenue-generating platforms.
-
Capital-efficient commercialisation via partners. Per-test arrangements (4Cyte), contract manufacturing (Quansys), software integration (MedicalDirector) and distribution partners (geneType) avoid fixed-cost build-out.
-
Evidence and reimbursement. Real-world data from the Access Program, peer-reviewed publication, health-economic modelling (October 2026) and the NHS evaluation are intended to support future public funding.
-
Platform synergy. geneType's enhanced CRC risk model is positioned to identify high-risk individuals for ColoSTAT triage, creating a "risk assessment → detection" pathway.
The FY26 Directors' Report states Rhythm enters FY2027 with a clear operational focus on converting clinical interest into sustained test volumes. Note 13 adds that the company is not actively pursuing additional investments in the short term while it integrates and grows existing businesses.
Strategic initiatives — last 24 months
| Initiative | Date | Description | Status |
|---|---|---|---|
| geneType acquisition | Dec 2024–Jan 2025 | Distressed acquisition from GTG administrators | Completed; NATA reinstated |
| ColoSTAT Gen2 multiplex | Dec 2024 | Single-reaction kit lowering COGS | Beta delivered; supply contracted |
| ISO 15189:2022 update | Dec 2025 | Laboratory accreditation | Achieved |
| NHS England evaluation | Dec 2025–ongoing | Multi-phase independent evaluation at Southern Hub | Phase 1 (tech transfer) complete Sep 2026 |
| ColoSTAT Access Program | Feb 2026 | Capped program for real-world evidence | Ongoing; repeat clinical ordering reported |
| Quansys manufacturing | Feb 2026 | Multi-year supply; two years fixed pricing | Active |
| 4Cyte collection network | Feb 2026 (expanded twice) | 1,000+ centres available; 100+ activated | Active |
| NATA accreditation of ColoSTAT service | Mar 2026 | Clinical testing accreditation | Achieved |
| geneType SE Asia distribution | Mar 2026 | Philippines initial market | First sale achieved |
| AGRF partnership | Q3 FY26 | Domestic geneType scale-up | Active |
| Catch Bio (US) | Dec 2025 | Marketing of geneType to US members | Active |
| Cancer IQ (US) | FY26 | Platform partnership for geneType | Active |
| Memorial Sloan Kettering collaboration | H1 FY26 | Scientific validation of geneType | Active |
| BIO International 2026 | Jun 2026 | Partnering meetings | Multiple opportunities reported |
| GP awareness campaign (Ausdoc) | Jul 2026 | ~20,000 GPs, >50% of eastern-states GP audience | Running |
| TGA in-house IVD notification | Aug 2026 | Regulatory compliance for in-house use | Accepted |
| MedicalDirector integration | Aug 2026 | Electronic ordering | Live; further integrations planned |
| Health-economic study | Oct 2026 | Public hospital colonoscopy demand model | Published |
| US reimbursement strategy for geneType | FY27 | In development | Planned |
ESG and cost programs
No formal sustainability targets or quantified cost-reduction program have been announced. The FY26 risk discussion notes management can scale back R&D and other activities if required to preserve liquidity.
Management guidance and targets
| Item | Guidance | Source |
|---|---|---|
| Cash runway | Cash reserves expected to fund operations through Q4 FY27 | Q4 FY26 Appendix 4C (30 Jul 2026) |
| geneType | Stronger sales growth expected in Q3 FY26 from partnerships | Q2 FY26 Appendix 4C |
| ColoSTAT Gen2 | Commercial launch targeted late FY26 | FY25 Annual Report |
| Implied revenue target (incentive hurdle) | A$1.5M revenue by June 2027; A$0.15M in three other countries | FY26 Remuneration Report |
| Formal revenue or earnings guidance | Not provided | — |
Products & Services
ColoSTAT platform
| Product / service | Description and capabilities | Target customer | Launch / version | Pricing |
|---|---|---|---|---|
| ColoSTAT test (laboratory-developed / in-house IVD) | Venous blood test measuring five specific protein biomarkers that rise or fall in the presence of colorectal tumours; result indicates likelihood of CRC. Positioned as a triage test for symptomatic patients and as an alternative for people unable or unwilling to use stool-based FIT screening. Historically indicated for adults aged 40–85 at average risk | GPs, specialists, symptomatic patients, screening-hesitant individuals | First commercial sale March 2026; NATA accreditation of clinical testing service March 2026; TGA in-house IVD notification accepted August 2026 | Patient self-pay; not Medicare funded. Health-economic study assumed A$250 per test (Oct 2026). Access Program initially provided free tests to establish workflows |
| ColoSTAT Gen2 multiplex kit | Combines the previously separate biomarker assays into a single reaction per patient sample, lowering cost of goods; beta release candidate kits delivered December 2024. FY25 annual report targeted commercial launch in late FY26 | Rhythm's own laboratory; third-party laboratories (e.g., NHS Southern Hub) | Beta delivered Dec 2024; commercial supply via Quansys from Feb 2026 | — |
| ColoSTAT Access Program | Capped direct-referral program (initially 20 participating clinicians nationally) designed to generate real-world evidence for reimbursement and partner discussions | Early-adopter clinicians | First physician enrolled 11 Feb 2026 | Initial tests free; transitioning to paid |
| UKCA-marked ColoSTAT kit | Conformity with European IVD Directive 98/79/EC and UKCA requirements, enabling marketing in Great Britain | UK laboratories / NHS | UKCA granted 2023 | — |
| ColoSTAT electronic ordering | Test request form integrated into MedicalDirector GP clinical software; further integrations in progress | GPs | Live 1 Aug 2026 | Not applicable |
Clinical performance data: Study 7 (815 patients, 11 Australian sites) reported 81% sensitivity and 91% specificity (company announcement, 2022). In FY26 the clinical performance data were published in a peer-reviewed journal (FY26 Directors' Report).
geneType platform
| Product / service | Description | Target customer | Status |
|---|---|---|---|
| geneType Cancer Risk Assessment (multi-cancer) | Integrates genetic profile (polygenic risk score from saliva/buccal sample), clinical factors and family history to estimate risk across up to six cancers | Clinicians, genetic counsellors; US prevention platforms | Marketed in Australia and US |
| geneType Colorectal Cancer Risk Test (enhanced, Jan 2026) | Next-generation CRC risk model delivered ahead of schedule in Q2 FY26; positioned to identify high-risk individuals who can then be triaged with ColoSTAT | Clinicians; ColoSTAT cross-sell | Released Jan 2026 |
| geneType Breast Cancer Risk | Polygenic + clinical breast cancer risk assessment | Women, clinicians | Marketed |
| geneType Ovarian Cancer Risk | Risk model validated by Harvard Medical School researchers (announced Q2 FY26) | Women, clinicians | Marketed |
| geneType Prostate, Pancreatic, Melanoma risk tests | Polygenic risk assessment for each cancer type | Clinicians | Marketed |
| geneType Cardiometabolic tests | Coronary artery disease, atrial fibrillation, type 2 diabetes risk | Clinicians | Marketed |
| Molecular genetics services | DNA extraction, predictive genetic testing, primary/secondary/tertiary bioinformatic analysis | Research and clinical clients | Inherited from Genetic Technologies |
The March 2026 Southeast Asian distribution announcement describes the portfolio as nine clinically validated genetic risk tests. Pricing for geneType tests is not publicly disclosed in the documents reviewed.
Pipeline / earlier-stage programs
| Program | Status |
|---|---|
| Breast cancer protein biomarkers (blood) | Preliminary assessment reported positive results (pre-2024); effectively returned to pre-clinical following 2023 strategic review |
| Pan-cancer / multi-cancer platform | Program commenced pre-2023 per November 2022 Bell Potter presentation; current status not publicly disclosed |
| geneType US reimbursement strategy | In development (Q4 FY26 activities report) |
Financial Narrative
Income statement: notes and sources
Notes: FY2025–FY2026 line items from FY26 Appendix 4E (P&L, Notes 3, 4, 6). Net loss and basic EPS for FY2022–FY2024 from the five-year table in the FY26 Remuneration Report. FY2023–FY2024 total income from aggregator (stoxray) data. FY2022–FY2024 weighted average shares are derived (net loss ÷ basic EPS) and therefore approximate. EBITDA = loss + D&A + finance expense − interest income (analyst calculation). Revenue CAGR over five years is not meaningful because the base year has nil sales; FY25→FY26 sales growth was 239.6%. Gross, operating and net margins on sales revenue are not meaningful (FY26 gross margin on sales −322%; net loss equal to ~69x sales).
Balance sheet: notes and sources
Notes: FY2025–FY2026 from FY26 Appendix 4E. FY2024 cash, equity, accumulated losses and licence carrying value from FY26 statement of changes in equity, cash flow statement and Note 7 movement schedule (opening balances). FY2023–FY2024 debt figures from aggregator (stoxray). FY2026 short-term borrowings of A$85,298 are a small loan following repayment of the A$1.0M facility in Q2 FY26.
Cash flow: notes and sources
Notes: FY2025–FY2026 from FY26 Appendix 4E cash flow statement. FY2023–FY2024 operating cash flow and equity proceeds from aggregator (stoxray) data, labelled there as "proceeds from repurchase of equity" but representing equity issuance. Q4 FY26 operating outflow was A$1.671M (Appendix 4C, 30 July 2026).
Ratios
Notes: Analyst calculations from FY26 Appendix 4E. FY2025 ROE uses average of FY24 equity (A$867k) and FY25 equity (A$660k). n/m = not meaningful given losses or negligible sales. (Ratio table uses n/m text because ratios are not chartable time series.)
Commentary on trends, inflections and drivers
Loss trajectory. Statutory losses fell steadily from A$8.79M (FY22) to A$3.83M (FY25) as the company retreated from the expensive 2021–2023 regulatory push, cut R&D after the TGA withdrawal, and restructured under new management. FY26 reversed that trend, with the loss widening 55% to A$5.93M. The Directors attribute the increase mainly to people and commercialisation costs: employment costs rose A$484k (+14%) to A$3.93M, office and administration rose A$354k (+21%) to A$2.02M (marketing, accreditation, investor relations), and cost of goods sold rose to A$360k as the laboratory began processing clinical samples. R&D expensed actually fell 25% to A$1.04M, reflecting the pivot from development to commercial execution.
The R&D refund distortion. The single largest swing factor in reported results is the timing of the Australian R&D tax incentive refund, which Rhythm recognises as income only when received (cash basis, relating to the prior year's claim). FY25 benefited from a A$3.17M refund (relating to FY24's heavier spend), while FY26 received only A$1.58M (relating to the leaner FY25). Excluding refund income, the underlying pre-refund loss was approximately A$7.0M in FY25 and A$7.5M in FY26 — a more stable picture of the true cost base, with FY26 roughly 8% higher. Investors should expect a further, likely smaller, refund in FY27 relating to FY26's reduced R&D spend.
Revenue inflection — real but tiny. Sales revenue more than tripled to A$85,339 in FY26, with cash receipts from customers of A$72,898. This confirms the end-to-end commercial pathway works but does not yet register against a A$7M+ annual cost base. Gross profit on sales remains negative (−A$275k), which is expected at sub-scale laboratory volumes but signals that volume, not price, is the binding constraint.
Balance sheet repair. FY26 equity raises (A$3.75M placement at A$0.09 in August 2025 and A$5.28M from the underwritten exercise of RHYO options at A$0.20 in April 2026) lifted net assets from A$0.66M to A$3.64M, repaid the A$1.0M loan, and moved working capital from a A$347k deficit to a A$2.72M surplus. Net tangible assets per share turned positive (0.73 cents). However, dilution was significant: shares on issue grew 25% (from 290.3M to 364.1M), and the underwriter received share-based consideration valued at A$1.46M (recorded within capital raising costs), meaning effective raising costs were roughly A$2.0M on A$9.2M gross — about 22% of proceeds.
Liquidity and going concern. The auditor again flagged a material uncertainty relating to going concern. At FY26 operating burn (A$5.23M, or ~A$436k per month), the A$3.36M year-end cash balance represents about 7–8 months of runway before the expected FY26 R&D refund. Management's Q4 FY26 guidance is that cash reserves fund operations through Q4 FY27 — a statement that presumably assumes the R&D refund and some cost discipline, and which implicitly signals a capital raise is likely before or during calendar 2027. The 64.6M RHYOA options (A$0.20, expiring November 2027) represent a potential A$12.9M inflow but are deeply out of the money at ~A$0.08.
Goodwill sensitivity. The A$531k goodwill from the geneType acquisition survived FY26 impairment testing, but the disclosed sensitivity is striking: impairment would be required if revenue growth falls below 170% per year over the three-year forecast period or if the pre-tax discount rate rises from 20% to 20.75%. The headroom is therefore extremely thin, and the auditor designated goodwill carrying value a key audit matter. Separately, the parent entity recorded a A$3.39M impairment of other financial assets (investments in/loans to subsidiaries) within the Deed of Cross Guarantee group — eliminated on consolidation but indicative of how management views recoverability of intercompany funding to the geneType/US operations.
Half-year phasing. H1 FY26 loss was A$2.26M (Appendix 4D), implying a H2 FY26 loss of about A$3.67M — consistent with ramping commercial costs after ColoSTAT launch in December 2025 and the 4Cyte, marketing and GP campaigns in the second half.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment sales revenue (AUD K) | 0 | 25.1 | 85.3 |
Total income incl. R&D refund and interest (AUD K) | 1,690 | 3,326 | 1,741 |
Segment loss before tax (AUD K) | -6,857 | -3,829 | -5,930 |
Sales revenue YoY growth (%) | — | — | 239.6 |
Contribution of segment to total sales (%) | 100 | 100 | 100 |
Platform Details
| Platform | Contents | Legal vehicle(s) | Revenue disclosure |
|---|---|---|---|
ColoSTAT | Blood-based colorectal cancer test (5 protein biomarkers); Gen2 multiplex kit; in-house laboratory testing service; Access Program | Rhythm Biosciences Ltd; Vision Tech Bio Pty Ltd; Rhythm Biosciences UK Ltd | — |
geneType | Nine polygenic/clinical risk assessment tests; molecular genetics services (DNA extraction, bioinformatics) | RHY GeneType Pty Ltd; IchorDX, Inc. (US) | geneType contributed A$25,126 revenue and a A$1.21M loss from 23 Dec 2024 to 30 Jun 2025 (FY26 Note 8); FY26 split not disclosed |
“—” = not publicly disclosed.
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Sales revenue (AUD K) | 0 | 0 | 0 | 25.1 | 85.3 |
R&D tax refund income (AUD K) | — | — | — | 3,166.3 | 1,575.9 |
Interest income (AUD K) | — | — | — | 134.3 | 76.4 |
Total income (AUD K) | — | 3,096 | 1,690 | 3,326.2 | 1,740.7 |
Cost of goods sold (AUD K) | — | — | — | 224.9 | 360.0 |
Gross profit on sales (AUD K) | — | — | — | -199.8 | -274.6 |
Employment costs (AUD K) | — | — | — | 3,448.0 | 3,932.2 |
Office and administration (AUD K) | — | — | — | 1,668.0 | 2,021.9 |
R&D costs expensed (AUD K) | — | — | — | 1,383.9 | 1,039.9 |
Depreciation and amortisation (AUD K) | — | — | — | 196.8 | 189.3 |
Finance expense (AUD K) | — | — | — | 66.7 | 74.8 |
EBITDA (AUD K) | — | — | — | -3,700.2 | -5,742.4 |
Operating income / EBIT excl. net interest (AUD K) | — | — | — | -3,897.0 | -5,931.7 |
Pre-tax income (AUD K) | -8,793.5 | -8,217.6 | -6,856.8 | -3,829.4 | -5,930.1 |
Net income (AUD K) | -8,793.5 | -8,217.6 | -6,856.8 | -3,829.4 | -5,930.1 |
EPS basic (A$ cents) | -4.19 | -3.79 | -3.00 | -1.42 | -1.77 |
EPS diluted (A$ cents) | -4.19 | -3.79 | -3.00 | -1.42 | -1.77 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Weighted avg shares (M) | 209.9 | 216.8 | 228.6 | 269.3 | 334.2 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD K) | — | — | — | 2,831.8 | 4,776.8 |
Cash and equivalents (AUD K) | — | — | 709.5 | 1,397.2 | 3,355.3 |
Term deposits (AUD K) | — | — | — | 85.0 | 85.0 |
Short-term borrowings (AUD K) | — | 85 | 78 | 1,000.0 | 85.3 |
Lease liabilities current (AUD K) | — | — | — | 105.4 | 86.8 |
Lease liabilities non-current (AUD K) | — | — | — | 1.9 | 75.8 |
Total debt incl. leases (AUD K) | — | 170 | 327 | 1,107.3 | 248.0 |
Net debt (negative = net cash) (AUD K) | — | — | — | -289.9 | -3,107.3 |
Total equity (AUD K) | — | — | 867.2 | 659.9 | 3,637.2 |
Goodwill (AUD K) | 0 | 0 | 0 | 531.0 | 531.0 |
Other intangibles — CSIRO licence (AUD K) | — | — | 354.1 | 318.1 | 282.2 |
Working capital (AUD K) | — | — | — | -347.4 | 2,715.2 |
Accumulated losses (AUD K) | — | — | 38,674.2 | 42,503.5 | 48,433.6 |
NTA per share (A$ cents) | — | — | — | -0.10 | 0.73 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD K) | — | — | — | 22.2 | 72.9 |
R&D tax refund received (AUD K) | — | — | — | 3,166.3 | 1,575.9 |
Operating cash flow (AUD K) | — | -6,958 | -6,137 | -2,921.3 | -5,233.0 |
Capex — plant and equipment (AUD K) | — | — | — | 23.2 | 25.8 |
Free cash flow (AUD K) | — | — | — | -2,944.5 | -5,258.8 |
Acquisition payments (AUD K) | 0 | 0 | 0 | 519.8 | 0 |
Equity raised gross (AUD K) | — | 3,716 | 2,897 | 3,500.1 | 9,025.8 |
Capital raising costs (AUD K) | — | — | — | 219.1 | 536.0 |
Net borrowings (AUD K) | — | — | — | 1,000.0 | -1,166.9 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE (% on average equity) | -499 | -276 |
ROA (% on average assets) | — | -156 |
ROIC (%)
| ROIC (%) | n/m | n/m |
|---|---|---|
Current ratio (x) | 0.84 | 3.61 |
Debt / equity incl. leases (x) | 1.68 | 0.07 |
Net debt / EBITDA (x)
| Net debt / EBITDA (x) | n/m | n/m |
|---|---|---|
Interest coverage (x) | n/m | n/m |
Asset turnover on sales (x) | — | 0.02 |
Cash conversion cycle (days) | n/m | n/m |
Operating cash burn per month (AUD K) | 243 | 436 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia (AUD K) | 0 | — | — |
United States (AUD K) | 0 | — | — |
Southeast Asia (AUD K) | 0 | 0 | — |
United Kingdom (AUD K) | 0 | 0 | 0 |
Total sales revenue (AUD K) | 0 | 25.1 | 85.3 |
Platform × Geography Details
| Platform × geography | Australia | United States | Southeast Asia | United Kingdom |
|---|---|---|---|---|
ColoSTAT | Commercial (in-house IVD; first sale Mar 2026) | Not launched | Not launched | NHS evaluation; UKCA marked; tech transfer complete |
geneType | Commercial (AGRF scale-up partnership) | Commercial (Catch Bio, Cancer IQ; US lab lease acquired) | First clinical sale (Philippines) | Not launched |
Share Price and Share Count (M)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 1.15 | 0.41 | 0.06 | 0.054 | 0.091 |
Shares on issue at 30 June (M) | — | — | 252.6 | 290.3 | 364.1 |
Market cap at 30 June (AUD Mn) | — | — | 15.2 | 15.7 | 33.1 |
Share Price & Returns
| Horizon | Approximate return | Basis |
|---|---|---|
1-year (Oct 2025 → Sep 2026) | Roughly −10% | ~A$0.090 (Nov 2025 option grant-date price) to A$0.081 (29 Sep 2026) |
3-year | Roughly −70% or worse | Shares traded near A$0.28+ in October 2023 per Reuters (Feb 2026 high was the highest since 11 Oct 2023) |
5-year | Roughly −93% | Shares traded ~A$1.23 in September 2021 |
52-week range | A$0.075 – A$0.28 | Stocklight / Yahoo Finance data, 2026 |
Valuation Multiples
| Multiple | Rhythm | Comment |
|---|---|---|
Market capitalisation | ~A$29.5M | 364.06M shares |
Enterprise value | ~A$26.4M | Less FY26 net cash of A$3.1M |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales (FY26) | ~310x | On A$85k sales |
P/B (FY26) | ~8.1x | On A$3.64M net assets |
Capital Markets
| Item | Status |
|---|---|
Analyst coverage | One analyst per Simply Wall St; TipRanks shows most recent rating as Hold with A$0.18 price target (circa April 2026) |
Dividend history | No dividends paid since IPO |
Dividend policy | None; capital retained for commercialisation |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | A$85k loan (current); lease liabilities A$86.8k (current), A$75.8k (non-current); no long-term debt |
Potential equity inflows | 64,621,132 RHYOA options at A$0.20 (expiry 30 Nov 2027) ≈ A$12.9M if fully exercised; currently out of the money |
Analyst Conclusions
Management guidance
Management has not provided revenue or earnings guidance. The only explicit financial guidance is that cash reserves are expected to fund operations through Q4 FY27 (Q4 FY26 Appendix 4C). Directors expect an FY26 R&D refund and retain the option to scale back activity. Incentive hurdles imply an internal ambition of A$1.5M revenue by June 2027 and A$0.15M from three non-Australian markets.
Consensus expectations
No published consensus revenue or earnings forecasts are available.
Bull case
-
Infrastructure is complete, so incremental volume drops through. With accreditation, TGA notification, contract manufacturing, a 100+ site collection network and GP software ordering all in place, the fixed-cost base is largely set; each additional A$250 test should improve gross margin from today's negative level.
-
NHS validation could re-rate the company. Successful completion of the patient-sample phases at the Southern Hub would make ColoSTAT one of very few blood CRC tests independently evaluated within NHS England's screening system, supporting licensing or kit-supply deals well beyond Rhythm's ~A$26M enterprise value.
-
Public-system economics are compelling. The October 2026 model, comparing a A$250 blood test with a A$3,163 colonoscopy, gives health departments a quantified reason to trial ColoSTAT for colonoscopy triage, potentially unlocking funded volumes in Australia.
Bear case
-
Commercial traction is not yet visible in the numbers. FY26 sales were A$85k, receipts A$73k, and gross profit negative; reaching the A$1.5M FY27 hurdle requires roughly 17x growth, while goodwill impairment is triggered below 170% annual growth.
-
Dilution is structural. At ~A$5.2M annual operating burn and A$3.4M cash, another raise appears likely within 12 months, at a share price that has fallen ~70% from its February 2026 high and with a 64.6M out-of-the-money option overhang.
-
The evidentiary and competitive bar keeps rising. Guardant's Shield has FDA approval, Medicare coverage and ~87,000 tests in 2025; Rhythm relies on a single 2021–2022 Australian study, an in-house IVD pathway and self-pay patients, with no reimbursement in any jurisdiction.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Q1 FY27 Appendix 4C | Late Oct 2026 | Customer receipts, test volumes, burn rate |
| 2026 AGM | Likely Nov 2026 (date per 29 Sep notice) | Board composition, remuneration vote, capital management resolutions |
| NHS evaluation Phase 2 (analytical testing on patient samples) | FY27 | Performance on NHS samples; next-stage scope |
| FY26 R&D tax refund | H1 FY27 | Size (likely below FY25's refund given lower R&D) |
| Additional GP software integrations | FY27 | Ordering volume impact |
| Reimbursement engagement (Medicare / state health) | FY27 | Any pilot or funding pathway |
| geneType US reimbursement strategy | FY27 | Payer progress; US revenue |
| CFO appointment | FY27 | Finance leadership stability |
| Capital raising | Likely H2 FY27 | Price, size, dilution |
| H1 FY27 results | ~17 Feb 2027 | Revenue run-rate vs A$1.5M hurdle |
Concluding analyst verdict
Rhythm Biosciences has done the unglamorous work that its 2021-era valuation skipped. In the past 12 months it has secured laboratory accreditation, NATA approval for the ColoSTAT clinical service, a TGA in-house IVD notification, a US contract manufacturer with fixed pricing, a per-test collection network spanning more than 100 activated sites, electronic GP ordering, a health-economic model, and — most strategically — an NHS England evaluation that has already cleared its technology-transfer phase. Management, now led by a commercially seasoned CEO and an independent MedTech chair, has reframed the company from a single-asset regulatory gamble into a two-platform diagnostics service business. That is genuine progress.
The financial statements, however, describe a business that has proven its pathway rather than its demand. FY26 sales of A$85,339 against a pre-refund loss of roughly A$7.5M, negative gross profit, a going-concern material uncertainty, goodwill headroom that evaporates below 170% annual growth, and a 25% increase in share count in a single year all point to a company whose equity value depends on events that have not yet occurred. The April 2026 ASX query and the post-underwriting share-price slide have also dented the credibility capital that a serial raiser needs.
At an enterprise value near A$26M, the market is pricing ColoSTAT as an option rather than a business — which is a defensible stance. The asymmetry is real: a favourable NHS outcome, a public-hospital pilot, or evidence of sustained GP-driven volume could each justify a multiple of today's valuation, while failure on any of them leaves an under-funded micro-cap facing dilutive raises against well-capitalised blood-test and stool-test incumbents.
Verdict: a high-risk, binary-leaning speculative position. The key evidence to demand over the next two quarters is simple: quarterly customer receipts trending decisively above A$100k and a clean progression of the NHS evaluation. Without both, the bear case dominates.
Principal sources: Rhythm Biosciences FY26 Appendix 4E and Audited Financial Report (27 Aug 2026); Half-Year Report and Appendix 4D (18 Feb 2026); Quarterly Activities Reports and Appendix 4C (23 Jan, 30 Apr, 30 Jul 2026); ASX announcements dated 9 Dec 2025, 10 Dec 2025, 26 Feb 2026, 4 Mar 2026, 2 Jul 2026, 20 Aug 2026, 22 Sep 2026, 7 Oct 2026; Response to ASX Query (14 Apr 2026); geneType acquisition announcements (23 Dec 2024, 15 Jan 2025); Bell Potter Healthcare Conference presentation (Nov 2022); Exact Sciences FY2025 results (13 Feb 2026); Guardant Health FY2025 results (financial media, Feb 2026); market data from Listcorp, Stocklight, InvestSMART, Investing.com, Simply Wall St, TipRanks, stoxray and Reuters; historical coverage from Stockhead, Biotech Daily and Stocks Down Under.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Independence |
|---|---|---|---|---|
Gavin Fox-Smith | Non-Executive Chairman | Director 2 Dec 2024; Chair from 5 Nov 2025 | 38-year MedTech career; former MD Australia/NZ and VP Asia Pacific, Johnson & Johnson Medical Devices; former CEO of Omnigon (ostomy care); Chair of ANDHealth; NED of Bowel Cancer Australia and SAN Foundation; former Chair of the Medical Technology Association of Australia; GAICD | Independent |
Dr David Atkins | Managing Director and CEO | CEO 13 May 2024; MD 30 Sep 2024 | ~30 years across pharma, devices and diagnostics; senior roles at Congenica (UK), Veridex (US), Gene Shears (Australia), Johnson & Johnson and Danaher. MBA (Finance), Columbia Business School; PhD Molecular Virology, John Innes Institute; Postgraduate Certificate in Pharmacology, UNSW; BSc, University of East Anglia | Executive |
Susan (Sue) MacLeman | Non-Executive Director | 31 Jan 2023 (Deputy Chair to 2 Dec 2024) | 30+ years as pharma/biotech/medtech executive; former CEO and director of ASX-, AIM- and Nasdaq-listed healthtech companies; B.Pharm (UQ), LLM (Deakin), Master of Marketing (MBS); Fellow and NED of ATSE; member of Commonwealth National Research Infrastructure Advisory Group | Independent |
Maureen Baker | Non-Executive Director | 27 Aug 2026 | Capital markets, investment banking and securities background; boards of Acorn Capital Investment Fund (ASX: ACQ) and Vmoto (ASX: VMT) | Independent (presumed) |
Carl Stubbings | Non-Executive Director | 27 Aug 2026 | Commercial and operational experience across biotech and diagnostics, including commercialising diagnostic products in Australia and internationally | Independent (presumed) |
Executive Leadership Team
| Name | Title | Tenure | Notes |
|---|---|---|---|
Dr David Atkins | MD & CEO | Since May 2024 | See above |
Chief Financial Officer | Vacant / not disclosed | Todd Perkinson resigned 19 Dec 2025 | Successor not publicly disclosed in documents reviewed; financial controller role previously held by Guy Carisbrooke (resigned 21 Feb 2025) |
Mark Licciardo | Company Secretary | Since 6 Jan 2025 | Founder of Mertons Corporate Services (now Acclime Australia); director of Frontier Digital Ventures |
Chief Operations Officer | Named in Dec 2024 ColoSTAT Gen2 announcement | — | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Cash salary/fees | Bonus | Leave provisions | Superannuation | Equity-based | Total | % performance-based |
|---|---|---|---|---|---|---|---|
D Atkins (MD & CEO) | 370,372 | 50,000 | 18,429 | 45,735 | 78,069 | 562,605 | 22.8 |
G Fox-Smith (Chair) | 78,672 | 0 | 0 | 8,391 | 21,428 | 108,491 | 19.8 |
S MacLeman (NED) | 46,875 | 0 | 0 | 5,625 | 12,857 | 65,357 | 19.7 |
O Buttula (former Chair, to 5 Nov 2025) | 36,313 | 0 | 0 | 4,358 | 0 | 40,671 | 0 |
T Perkinson (former CFO, to 19 Dec 2025) | 115,013 | 0 | -4,124 | 13,363 | -9,048 | 115,204 | 0 |
Total KMP | 647,245 | 50,000 | 14,305 | 77,472 | 103,306 | 892,328 | — |
Directors' Remuneration by Attribute
| Attribute | Status |
|---|---|
Board size | 5 (post 27 Aug 2026) |
Independent NEDs | 4 of 5 |
Chair / CEO separation | Yes — independent Non-Executive Chair |
Gender | 2 women (MacLeman, Baker) of 5 directors (40%) |
Board meetings FY26 | 9 (100% attendance by all serving directors) |
Committees | Not detailed in documents reviewed; Corporate Governance Statement (approved 29 Sep 2026) published on company website |
Remuneration consultant | None used in FY26 |
Clawback policy | Yes (applies to CEO incentives) |
Related-party transactions | None other than remuneration (FY25, FY26) |
Major Shareholders
| Holder | Shares | % at time of data | % of current 364.06M (approx.) | Notes |
|---|---|---|---|---|
Otto Buttula (and associated entities) | 36,384,575 | 12.8 | 10.0 | Former Chairman; ceased as director 5 Nov 2025 — current holding not reported post-departure |
Michelle Wing | 18,117,500 | 6.39 | 5.0 | Early backer (Wing family linked to IPO) |
Fidelity International Ltd | 17,511,734 | 6.17 | 4.8 | Increased stake in Feb and Apr 2025 |
Loumea Investment Pty Ltd | 8,052,520 | 2.84 | 2.2 | Private investment company (Richard Vom) |
Rojo Nero Capital Pty Ltd | — | 1.49 | — | — |
Top 25 holders combined | — | 41.99 | — | — |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Competitor | Segment | Product | Relative positioning |
|---|---|---|---|
Exact Sciences (Nasdaq: EXAS) | CRC screening (stool DNA) | Cologuard | Global category leader; FY2025 revenue US$3.25B, screening revenue US$2.53B |
Guardant Health (Nasdaq: GH) | CRC screening (blood, cfDNA) | Shield | FY2025 revenue US$982M; Shield revenue US$79.7M from ~87,000 tests; FDA-approved blood CRC screening test with Medicare coverage |
National FIT programs (e.g., Australia's NBCSP; NHS FIT) | CRC screening (stool immunochemical) | FIT kits | Incumbent standard of care; low-cost but under 50% participation in Australia (per Rhythm's Oct 2026 release) |
Colonoscopy providers | CRC diagnosis | Colonoscopy | Gold standard; ColoSTAT positions as triage to reduce unnecessary procedures |
Geneoscopy (private) | CRC screening (stool RNA) | ColoSense | US-focused stool-based alternative |
Freenome (private) | CRC screening (blood, multiomics) | Blood-based CRC test | — |
Epigenomics AG | CRC (blood, methylation) | Epi proColon | Earlier blood test with limited uptake (historical) |
Clinical Genomics | CRC recurrence (blood) | COLVERA | Niche recurrence monitoring |
GRAIL | Multi-cancer early detection | Galleri | MCED tests could subsume single-cancer blood tests |
Myriad Genetics | Polygenic/hereditary risk | RiskScore, MyRisk | Direct geneType competitor in US |
Ambry Genetics / Color Health / Genomics plc / Allelica | Polygenic risk | Various PRS offerings | Direct geneType competitors |
BCAL Diagnostics (ASX: BDX), INOVIQ (ASX: IIQ) | ASX micro-cap cancer diagnostics | Breast cancer blood tests and others | Peer group for investor capital |
Peer Comparison FY2026
| Metric | Rhythm Biosciences (FY26, AUD Mn) | Exact Sciences (FY25, USD Mn) | Guardant Health (FY25, USD Mn) |
|---|---|---|---|
Revenue | 0.085 | 3,250 | 982 |
Revenue growth (%) | 240 | 18 | 33 |
Net income | -5.93 | -208 | — |
Adjusted EBITDA | -5.74 | 400 | — |
CRC screening revenue | ~0.085 (incl. geneType) | 2,530 | 79.7 |



